Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University, Atlanta, Georgia, USA.
Division of Rheumatology, Department of Medicine, Emory University, Atlanta, Georgia, USA.
Immunol Rev. 2022 Aug;309(1):40-63. doi: 10.1111/imr.13115. Epub 2022 Jul 8.
Infection with SARS-CoV-2, the etiology of the ongoing COVID-19 pandemic, has resulted in over 450 million cases with more than 6 million deaths worldwide, causing global disruptions since early 2020. Memory B cells and durable antibody protection from long-lived plasma cells (LLPC) are the mainstay of most effective vaccines. However, ending the pandemic has been hampered by the lack of long-lived immunity after infection or vaccination. Although immunizations offer protection from severe disease and hospitalization, breakthrough infections still occur, most likely due to new mutant viruses and the overall decline of neutralizing antibodies after 6 months. Here, we review the current knowledge of B cells, from extrafollicular to memory populations, with a focus on distinct plasma cell subsets, such as early-minted blood antibody-secreting cells and the bone marrow LLPC, and how these humoral compartments contribute to protection after SARS-CoV-2 infection and immunization.
感染 SARS-CoV-2 是当前 COVID-19 大流行的病因,导致了超过 4.5 亿例病例和全球超过 600 万人死亡,自 2020 年初以来造成了全球混乱。记忆 B 细胞和长寿浆细胞(LLPC)产生的持久抗体保护是大多数有效疫苗的基础。然而,由于感染或接种疫苗后缺乏长期免疫,大流行一直难以结束。尽管免疫接种可以预防严重疾病和住院治疗,但突破性感染仍时有发生,这很可能是由于新的突变病毒和中和抗体在 6 个月后总体下降所致。在这里,我们回顾了 B 细胞的现有知识,从滤泡外到记忆群体,重点介绍了不同的浆细胞亚群,如早期产生的血液抗体分泌细胞和骨髓中的长寿浆细胞,以及这些体液区室如何在 SARS-CoV-2 感染和免疫后提供保护。